{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05849207",
            "orgStudyIdInfo": {
                "id": "IIT2022-03-PAQUETTE-GERIBMT"
            },
            "organization": {
                "fullName": "Cedars-Sinai Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant",
            "officialTitle": "IIT2022-03-Paquette-GeriBMT: A Phase I Study of De-Escalation of Post-Transplant Cyclophosphamide Dosing in Patients Aged >/= 70 Years Undergoing Conditioning With Fludarabine and Total Body Irradiation 800 cGy",
            "acronym": "GeriBMT",
            "therapeuticArea": [
                "Other"
            ],
            "study": "post-transplant-cyclophosphamide-in-patients-aged-years-undergoing-haploidentical-transplant"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-13",
            "studyFirstSubmitQcDate": "2023-05-05",
            "studyFirstPostDateStruct": {
                "date": "2023-05-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Ronald Paquette",
                "investigatorTitle": "Medical Director, Blood and Marrow Transplant Program",
                "investigatorAffiliation": "Cedars-Sinai Medical Center"
            },
            "leadSponsor": {
                "name": "Ronald Paquette",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \\>/= 70 years with hematologic malignancies.",
            "detailedDescription": "The patients will receive a standard dose, or a reduced amount of the immune suppressive drug, cyclophosphamide, that is routinely administered after the transplant procedure. The following procedures will be performed: cardiac MRI scans and/or transthoracic echocardiogram (TTE); laboratory tests, geriatric assessments and tests to measure strength and stability.\n\nParticipation in the study is expected to last up to one year with follow-up visits occurring on Day +30, Day +100, Day +180 and Day +365 following allogenic stem cell transplant."
        },
        "conditionsModule": {
            "conditions": [
                "Hematologic Malignancies"
            ],
            "keywords": [
                "Allogeneic Transplantation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Open-label trial\n\nDe-escalation of post-transplant cyclophosphamide dosing",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 26,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Open Arm",
                    "type": "EXPERIMENTAL",
                    "description": "All patients will receive cyclophosphamide on Day +3 and Day +4 following transplant.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.",
                    "armGroupLabels": [
                        "Open Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum grade acute GVHD by day +100 by Modified Keystone Criteria",
                    "description": "Evaluate the frequency of grade III/IV acute GVHD using Modified Keystone Criteria",
                    "timeFrame": "100 days post-transplant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to neutrophil and platelet engraftment",
                    "description": "Days to neutrophil and platelet engraftment since transplant",
                    "timeFrame": "60 days post-transplant"
                },
                {
                    "measure": "Non-Relapse mortality",
                    "description": "Rate of treatment-related mortality",
                    "timeFrame": "100 days post-transplant"
                },
                {
                    "measure": "Chronic Graft Versus Host Disease (GVHD) at 1 year",
                    "description": "* Rate and severity of patients with chronic GVHD at day 365 post-transplantation.\n* Chronic GVHD is when the donated stem cells attack the body after 100 days post-transplant. Chronic GVHD is defined by NIH Consensus Criteria for chronic GVHD.",
                    "timeFrame": "1-year post-transplant"
                },
                {
                    "measure": "Relapse",
                    "description": "Percentage of patients who relapse by year 1",
                    "timeFrame": "1-year post-transplant"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "Overall survival at 1 year",
                    "timeFrame": "1-year post-transplant"
                },
                {
                    "measure": "Graft Versus Host Disease (GVHD)-free and Relapse Free Survival",
                    "description": "Percentage of patients without relapse or GVHD at 1 year",
                    "timeFrame": "1-year post- transplant"
                },
                {
                    "measure": "Change in cardiac function",
                    "description": "Change in cardiac (heart) injury defined by any of an increase in T1 time \\> 500 ms from pre-transplant imaging, T2 time \\> 5 ms from pre-transplant imaging, or a decrease in left ventricular ejection fraction \\> 10% of the original measurement to below 53% from post-transplant imaging.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in active daily living",
                    "description": "Change in function over time as determined by Lawton Activities of Daily Living questionnaire.\n\n- Patients will choose either 0 or 1 to rate their level of function with 1 being the highest level of function.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in function",
                    "description": "Change in function over time as determined by the Patient-Reported Outcomes Measurement Information System (PROMIS) Cancer Function Brief 3-Dimensional Profile.\n\n- Patients will rate their physical condition and fatigue using an inverse 5-item likert scale where 5 represents the highest level of function or the greatest amount of impact on function.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in pain",
                    "description": "Change in pain over time as determined by the Patient-Reported Outcomes Measurement Information System (PROMIS) Cancer Function Brief 3-Dimensional Profile.\n\n- Patients will rate their level of pain using a scale from 0 to 10 with 10 being the highest level of pain.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in physical function",
                    "description": "Change in lower limb functioning over time as evaluated by the Short Physical performance Battery. (SPPB).\n\n- Patients will complete a series of tests evaluating balance, speed and standing capabilities. Patients will be rated using a scale of 0 to 12 where a score of less than 10 indicates mobility limitations.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in grip strength",
                    "description": "Change in grip strength as measured using the Jamar dynamometer (device used to measure grip)",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in cognitive function",
                    "description": "Change in cognitive function over time using the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognition questionnaire.\n\n-Patients will rate their cognitive ability on a scale of 1 to 5 with 5 representing the least amount of difficulty.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                },
                {
                    "measure": "Change in mental health",
                    "description": "Change in mental health over time using the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Depression Questionnaire.\n\n- Patients will rate their level of depression on a scale of 1 to 5 with 5 representing the greatest level of depression.",
                    "timeFrame": "From 60 days prior to transplant to 365 days post-transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient age \\>/= 70 years\n* Patient has a related donor who is a human leukocyte antigens (HLA) haploidentical match\n* Patient and Donor sign the Informed Consent Form for the study\n* Patient meets standard criteria for allogeneic stem cell transplant\n* Patient is deemed suitable to receive Flu/TBI 800 conditioning regimen as standard of care transplant\n* Donor is willing to donate peripheral blood stem cells (PBSC)\n\nExclusion Criteria:\n\n* Patient has a diagnosis of myelofibrosis\n* Patient has high titer antibodies (\\>10,000 mean fluorescent intensity) against one or more donor HLA antigens\n* Patient has undergone prior autologous or allogeneic stem cell transplant\n* Inability to collect at least 3 x 10\\^6 CD34+ PBSCs/kg recipient weight from the donor\n* Requiring sedation for cardiac MRIs.\n* Prohibited Implants and/or Devices:\n\n  * Mechanical, magnetic or electrical activated implants (i.e. cardiac pacemakers, neurostimulators and infusion pumps)\n  * Ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged.\n* Subjects with claustrophobia, problems being in enclosed spaces, or inability to lie supine.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "70 Years",
            "stdAges": [
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amy Oppenheim",
                    "role": "CONTACT",
                    "phone": "310-423-3713",
                    "email": "Amy.Oppenheim@cshs.org"
                },
                {
                    "name": "Nadia Nassaj",
                    "role": "CONTACT",
                    "phone": "310-423-7735",
                    "email": "mehrnoosh.nassaj@cshs.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ronald Paquette, MD",
                    "affiliation": "Cedars-Sinai Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amy Oppenheim",
                            "role": "CONTACT",
                            "phone": "310-423-3713",
                            "email": "Amy.Oppenheim@cshs.org"
                        },
                        {
                            "name": "Nadia Nassaj",
                            "role": "CONTACT",
                            "phone": "310-423-7735",
                            "email": "mehrnoosh.nassaj@cshs.org"
                        },
                        {
                            "name": "John Chute, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Justin Darrah, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Akil Merchant, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Noah Merin, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Joshua Sasine, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Robert Vescio, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Arash Asher, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Philip Chang, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Alan Kwan, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Stephen Shiao, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Hannah Lee, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}